Universe Pharmaceuticals (UPC)
(Delayed Data from NSDQ)
$3.74 USD
+0.16 (4.47%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $3.73 -0.01 (-0.27%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Universe Pharmaceuticals INC falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 19 | 19 | 22 | 10 | 3 |
Receivables | 11 | 15 | 16 | 11 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 2 | 2 | 2 | 3 |
Other Current Assets | 4 | 5 | 10 | 0 | 0 |
Total Current Assets | 37 | 42 | 50 | 23 | 12 |
Net Property & Equipment | 4 | 4 | 5 | 4 | 5 |
Investments & Advances | 1 | 1 | 1 | 1 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 1 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 11 | 12 | 13 | 0 | 0 |
Total Assets | 53 | 60 | 70 | 29 | 18 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 3 | 5 | 3 | 2 |
Current Portion Long-Term Debt | 5 | 4 | 4 | 3 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 1 | 1 | 1 |
Other Current Liabilities | 1 | 3 | 0 | 1 | 0 |
Total Current Liabilities | 14 | 13 | 11 | 8 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14 | 13 | 11 | 8 | 5 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 29 | 29 | 29 | 4 | 4 |
Retained Earnings | 10 | 16 | 25 | 14 | 6 |
Other Equity | 0 | 1 | 5 | 3 | 2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 40 | 46 | 59 | 21 | 12 |
Total Liabilities & Shareholder's Equity | 53 | 60 | 70 | 29 | 18 |
Total Common Equity | 40 | 46 | 59 | 21 | 12 |
Shares Outstanding | 3.60 | 3.60 | 3.60 | NA | NA |
Book Value Per Share | 10.98 | 12.90 | 16.37 | 0.00 | 0.00 |
Fiscal Year End for Universe Pharmaceuticals INC falls in the month of September.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | 19 | -99,999 |
Receivables | NA | NA | NA | 11 | NA |
Notes Receivable | NA | NA | NA | 0 | NA |
Inventories | NA | NA | NA | 3 | NA |
Other Current Assets | NA | NA | NA | 4 | NA |
Total Current Assets | NA | NA | NA | 37 | NA |
Net Property & Equipment | NA | NA | NA | 4 | NA |
Investments & Advances | NA | NA | NA | 1 | NA |
Other Non-Current Assets | NA | NA | NA | 0 | NA |
Deferred Charges | NA | NA | NA | 1 | NA |
Intangibles | NA | NA | NA | 0 | NA |
Deposits & Other Assets | NA | NA | NA | 11 | NA |
Total Assets | NA | NA | NA | 53 | NA |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 0 | NA |
Accounts Payable | NA | NA | NA | 5 | NA |
Current Portion Long-Term Debt | NA | NA | NA | 5 | NA |
Current Portion Capital Leases | NA | NA | NA | 0 | NA |
Accrued Expenses | NA | NA | NA | 3 | NA |
Income Taxes Payable | NA | NA | NA | 0 | NA |
Other Current Liabilities | NA | NA | NA | 1 | NA |
Total Current Liabilities | NA | NA | NA | 14 | NA |
Mortgages | NA | NA | NA | 0 | NA |
Deferred Taxes/Income | NA | NA | NA | 0 | NA |
Convertible Debt | NA | NA | NA | 0 | NA |
Long-Term Debt | NA | NA | NA | 0 | NA |
Non-Current Capital Leases | NA | NA | NA | 0 | NA |
Other Non-Current Liabilities | NA | NA | 0 | NA | |
Minority Interest (Liabilities) | NA | NA | NA | 0 | NA |
Total Liabilities | NA | NA | NA | 14 | NA |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | NA |
Common Stock (Par) | NA | NA | NA | 0 | NA |
Capital Surplus | NA | NA | NA | 29 | NA |
Retained Earnings | NA | NA | NA | 10 | NA |
Other Equity | NA | NA | NA | 0 | NA |
Treasury Stock | NA | NA | NA | 0 | NA |
Total Shareholder's Equity | NA | NA | NA | 40 | NA |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 53 | NA |
Total Common Equity | 0 | 0 | 0 | 40 | 0 |
Shares Outstanding | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 10.98 | 0.00 |